Royalty Pharma reported first quarter 2026 Portfolio Receipts of $925 million, representing 10% year-over-year growth, driven by strong performance from key assets. Following the strong start to the year, the company raised its full-year 2026 guidance for Portfolio Receipts.
Key Highlights
- Portfolio Receipts grew 10% year-over-year to $925 million, while Royalty Receipts increased 13% to $887 million, led by strong contributions from Tremfya, Voranigo, and Evrysdi.
- The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.325 billion to $3.450 billion, up from the previous range of $3.275 billion to $3.425 billion.
- Capital deployment in the first quarter was $528 million, part of $1.25 billion in announced value for new royalty transactions, including R&D co-funding collaborations with Johnson & Johnson and Teva.